keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker lymphoma

keyword
https://www.readbyqxmd.com/read/27913492/frontline-strategy-for-follicular-lymphoma-are-we-ready-to-abandon-chemotherapy
#1
Nathan Fowler
Chemotherapy combinations have been the backbone of therapy for follicular lymphoma, and are associated with high initial response rates. Unfortunately, toxicity and secondary malignancies remain concerns, and most advanced-stage patients still relapse within 5 years, regardless of the regimen. Advances in the understanding of lymphoma biology have resulted in a new generation of noncytotoxic therapeutics with significant activity in follicular lymphoma. Recent studies exploring biological and targeted combinations in the frontline have shown promise, with response rates similar to chemotherapy...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27913491/prognostic-factors-in-follicular-lymphoma-new-tools-to-personalize-risk
#2
Carla Casulo
Follicular lymphoma (FL) is the most common indolent lymphoma, and it has a long median overall survival (OS). However, the recent discovery of clinical and biological prognostic biomarkers in FL is shedding light on FL heterogeneity and the need for a precise and risk-stratified individual approach at diagnosis and relapse. Many FL patients who are asymptomatic with indolent disease can be vulnerable to the toxicity, emotional distress, and financial burden of overtreatment. Yet a subset of FL patients develop chemoresistance to standard chemoimmunotherapy, experience transformation to aggressive lymphoma and rapid progression, and represent the population most in need of novel therapies and curative approaches...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27912828/lung-cancer-biomarkers
#3
REVIEW
Pamela Villalobos, Ignacio I Wistuba
The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it is possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has led to accelerated development of new drugs for lung cancer treatment...
February 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27897325/the-biomarker-landscape-in-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#4
REVIEW
Brittany Dulmage, Larisa Geskin, Joan Guitart, Oleg E Akilov
The practice of preemptive individualized medicine is predicated on the discovery, development, and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis, and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicenter efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules...
November 28, 2016: Experimental Dermatology
https://www.readbyqxmd.com/read/27889782/molecular-pathology-a-requirement-for-precision-medicine-in-cancer
#5
Manfred Dietel
The increasing importance of targeting drugs and check-point inhibitors in the treatment of several tumor entities (breast, colon, lung, malignant melanoma, lymphoma, etc.) and the necessity of a companion diagnostic (HER2, (pan)RAS, EGFR, ALK, BRAF, ROS1, MET, PD-L1, etc.) is leading to new challenges for surgical pathology. Since almost all the biomarkers to be specifically detected are tissue based, a precise and reliable diagnostic is absolutely crucial. To meet this challenge surgical pathology has adapted a number of molecular methods (semi-quantitative immunohistochemistry, fluorescence in situ hybridization, PCR and its multiple variants, (pyro/Sanger) sequencing, next generation sequencing (amplicon, whole exome, whole genome), DNA arrays, methylation analyses, etc...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889686/microrna-181-contributes-to-downregulation-of-samhd1-expression-in-cd4-t-cells-derived-from-s%C3%A3-zary-syndrome-patients
#6
Rebecca Kohnken, Karthik M Kodigepalli, Anjali Mishra, Pierluigi Porcu, Li Wu
Sézary syndrome (SS) is a rare subtype of cutaneous T-cell lymphoma (CTCL) that is characterized by aggressive spread of neoplastic CD4+ T-cells from the skin into the bloodstream with metastasis to visceral organs. The deoxynucleoside triphosphohydrolase SAMHD1 is highly expressed in normal CD4+ T-cells, while its expression is down-regulated in CD4+ T-cells from SS patients. MicroRNA (miR) dysregulation is an important epigenetic mechanism in the pathogenesis and progression of SS. MiR-181 has been shown to inhibit SAMHD1 expression in cell lines and was identified as an important prognostic biomarker in CTCL...
November 17, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27889037/pathology-of-anal-cancer
#7
REVIEW
Paulo M Hoff, Renata Coudry, Camila Motta Venchiarutti Moniz
Anal canal cancer is rather an uncommon disease but its incidence is increasing. Squamous cell carcinoma (SCC) is the most frequent primary anal neoplasm and can encompass a variety of morphologies. HPV infection has a key role in precancerous lesions and cancer development by the production of E6 and E7 oncoproteins. Anal squamous precancerous lesions are now classified according to the same criteria and terminology as their cervical counterparts. The p16 expression by immunohistochemistry is a surrogate marker for human papilloma virus (HPV)...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27882350/plasma-vesicle-mirnas-for-therapy-response-monitoring-in-hodgkin-lymphoma-patients
#8
Monique A J van Eijndhoven, Josée M Zijlstra, Nils J Groenewegen, Esther E E Drees, Stuart van Niele, S Rubina Baglio, Danijela Koppers-Lalic, Hans van der Voorn, Sten F W M Libregts, Marca H M Wauben, Renee X de Menezes, Jan R T van Weering, Rienk Nieuwland, Lydia Visser, Anke van den Berg, Daphne de Jong, D Michiel Pegtel
BACKGROUND. Cell-free circulating nucleic acids, including 22-nt microRNAs (miRNAs), represent noninvasive biomarkers for treatment response monitoring of cancer patients. While the majority of plasma miRNA is bound to proteins, a smaller, less well-characterized pool is associated with extracellular vesicles (EVs). Here, we addressed whether EV-associated miRNAs reflect metabolic disease in classical Hodgkin lymphoma (cHL) patients. METHODS. With standardized size-exclusion chromatography (SEC), we isolated EV-associated extracellular RNA (exRNA) fractions and protein-bound miRNA from plasma of cHL patients and healthy subjects...
November 17, 2016: JCI Insight
https://www.readbyqxmd.com/read/27873079/next-generation-predictive-biomarkers-for-immune-checkpoint-inhibition
#9
Yulian Khagi, Razelle Kurzrock, Sandip Pravin Patel
With the advent of targeted therapies, there has been a revolution in the treatment of cancer across multiple histologies. Immune checkpoint blockade has made it possible to take advantage of receptor-ligand interactions between immune and tumor cells in a wide spectrum of malignancies. Toxicity in healthy tissue, however, can limit our use of these agents. Immune checkpoint blockade has been approved in advanced melanoma, renal cell cancer, non-small cell lung cancer, relapsed refractory Hodgkin's lymphoma, and urothelial cancer...
November 21, 2016: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/27867542/the-expression-of-sall4-is-significantly-associated-with-egfr-but-not-kras-or-eml4-alk-mutations-in-lung-cancer
#10
Xiangbo Jia, Rulin Qian, Binbin Zhang, Song Zhao
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide; unfortunately, its prognosis is still very poor. Therefore, developing the target molecular is very important for lung cancer diagnosis and treatment, especially in the early stage. With this in view, spalt-like transcription factor 4 (SALL4) is considered a potential biomarker for diagnosis and prognosis in cancers, including lung cancer. METHODS: In order to better investigate the association between the expression of SALL4 and driver genes mutation, 450 histopathologically diagnosed patients with lung cancer and 11 non-cancer patients were enrolled to test the expression of SALL4 and the status of driver genes mutation...
October 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27863567/advancing-precision-nuclear-medicine-and-molecular-imaging-for-lymphoma
#11
REVIEW
Chadwick L Wright, Joseph J Maly, Jun Zhang, Michael V Knopp
PET with fluorodeoxyglucose F 18 ((18)F FDG-PET) is a meaningful biomarker for the detection, targeted biopsy, and treatment of lymphoma. This article reviews the evolution of (18)F FDG-PET as a putative biomarker for lymphoma and addresses the current capabilities, challenges, and opportunities to enable precision medicine practices for lymphoma. Precision nuclear medicine is driven by new imaging technologies and methodologies to more accurately detect malignant disease. Although quantitative assessment of response is limited, such technologies will enable a more precise metabolic mapping with much higher definition image detail and thus may make it a robust and valid quantitative response assessment methodology...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863540/comparison-of-serum-cytokine-levels-between-dogs-with-multicentric-lymphoma-and-healthy-dogs
#12
Jerome Calvalido, Geoffrey A Wood, Anthony J Mutsaers, Darren Wood, William Sears, J Paul Woods
In humans, multiple cytokines have been linked to the development of lymphoma, and are relevant biomarkers for response to chemotherapy and prognosis. In contrast, only a few circulating cytokines have been studied in dogs with lymphoma. We prospectively enrolled thirty-one dogs newly diagnosed with multicentric lymphoma. Immunophenotype was determined by flow cytometry in all dogs, separating them into 2 subgroups: B cell lymphoma (n=21) and T cell lymphoma (n=10). Nineteen healthy dogs were enrolled in the control group...
December 2016: Veterinary Immunology and Immunopathology
https://www.readbyqxmd.com/read/27844106/lymphoma-current-status-of-clinical-and-preclinical-imaging-with-radiolabeled-antibodies
#13
REVIEW
Christopher G England, Lixin Rui, Weibo Cai
Lymphoma is a complex disease that arises from cells of the immune system with an intricate pathology. While lymphoma may be classified as Hodgkin or non-Hodgkin, each type of tumor is genetically and phenotypically different and highly invasive tissue biopsies are the only method to investigate these differences. Noninvasive imaging strategies, such as immunoPET, can provide a vital insight into disease staging, monitoring treatment response in patients, and dose planning in radioimmunotherapy. ImmunoPET imaging with radiolabeled antibody-based tracers may also assist physicians in optimizing treatment strategies and enhancing patient stratification...
November 14, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27831501/characterizing-cd137-upregulation-on-nk-cells-in-patients-receiving-monoclonal-antibody-therapy
#14
A Makkouk, V Sundaram, C Chester, S Chang, A D Colevas, J B Sunwoo, H Maecker, M Desai, H E Kohrt
BACKGROUND: In the era of personalized cancer medicine, identifying techniques for effectively matching patients to efficacious treatments is a critical step in the treatment process. The advent of anti-cancer immunotherapies necessitates novel approaches to biomarker identification beyond traditional genomic profiling. One promising approach is incorporation of nomograms into treatment decisions. Nomograms are prediction tools, based on statistical modeling, designed to predict treatment outcomes...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27821903/proteomic-approaches-to-biomarker-discovery-in-cutaneous-t-cell-lymphoma
#15
REVIEW
Alexandra Ion, Iris Maria Popa, Laura Maria Lucia Papagheorghe, Cristina Lisievici, Mihai Lupu, Vlad Voiculescu, Constantin Caruntu, Daniel Boda
Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy...
2016: Disease Markers
https://www.readbyqxmd.com/read/27799345/fdg-pet-as-a-biomarker-for-early-response-in-diffuse-large-b-cell-lymphoma-as-well-as-in-hodgkin-lymphoma-ready-for-implementation-in-clinical-practice
#16
EDITORIAL
Josée M Zijlstra, Coreline N Burggraaff, Marie José Kersten, Sally F Barrington
No abstract text is available yet for this article.
November 2016: Haematologica
https://www.readbyqxmd.com/read/27795508/update-on-the-use-of-fdg-pet-ct-in-malignant-lymphoma
#17
Takashi Terauchi
This article aims to explain the current status of FDG-PET/CT in malignant lymphoma management by reviewing the new recommendations for evaluation, staging, and response assessment in patients with malignant lymphoma, published as the Lugano Classification in 2014. FDG-PET/CT was formally incorporated into standard staging for FDG-avid lymphoma in this new classification. Nearly all subtypes of malignant lymphoma are FDG-avid. In staging, the increased FDG uptake compatible with lymphoma is considered to represent involvement of lymphoma, regardless of size, and the FDG-avid lesion is potentially a good biopsy target...
2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/27786547/imaging-for-oncologic-response-assessment-in-lymphoma
#18
Naveen M Kulkarni, Daniella F Pinho, Srikala Narayanan, Avinash R Kambadakone, Jeremy S Abramson, Dushyant V Sahani
OBJECTIVE: The purpose of this article is to examine the role of different imaging biomarkers, focusing in particular on the use of updated CT and PET response criteria for the assessment of oncologic treatment effectiveness in patients with lymphoma but also discussing other potential functional imaging methods and their limitations. CONCLUSION: Lymph nodes are commonly involved by metastatic solid tumors as well as by lymphoma. Evolving changes in cancer therapy for lymphoma and metastases have led to improved clinical outcomes...
October 27, 2016: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/27783137/a-specific-mode-of-microsatellite-instability-is-a-crucial-biomarker-in-adult-t-cell-leukaemia-lymphoma-patients
#19
Kaname Miyashita, Kei Fujii, Kenichi Taguchi, Mototsugu Shimokawa, Mitsuaki A Yoshida, Yasunobu Abe, Jun Okamura, Shinya Oda, Naokuni Uike
PURPOSE: Microsatellite instability (MSI) has been a long-standing biomarker candidate for drug resistance in tumour cells. Despite numerous clinical studies, the data in the literature are not conclusive. The complexity of the MSI phenomenon in some malignancies may, at least partly, account for the discrepancy. In addition, methodological problems are also pointed out in the assay techniques. We previously established a unique fluorescent technique in which the major methodological problems in conventional assays are overcome...
October 25, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27774748/pretreatment-14-3-3-epsilon-level-is-predictive-for-advanced-extranodal-nk-t-cell-lymphoma-therapeutic-response-to-asparaginase-based-chemotherapy
#20
Yajuan Qiu, Zhiyuan Zhou, Zhaoming Li, Lisha Lu, Ling Li, Xin Li, Xinhua Wang, Mingzhi Zhang
PURPOSE: The aim of the present study was to identify the potential relevant biomarkers to predict the therapeutic response of advanced extranodal NK/T cell lymphoma(ENKTL) treated with asparaginase-based treatment. EXPERIMENTAL DESIGN: We used proteomic technology to identify differentially expressed proteins between chemotherapy-resistant and chemotherapy-sensitive patients. Then we used enzyme-linked immunosorbent assay to validate the predictive value of selective biomarkers...
October 24, 2016: Proteomics. Clinical Applications
keyword
keyword
7294
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"